Supplementary Data from Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
Open Access
- 3 April 2023
- other
- Published by American Association for Cancer Research (AACR)